
Graft-vs-Host Disease (GVHD)
Latest News

Advertisement
Latest Videos
CME Content
Advertisement
More News

Two existing, well-validated patient-reported outcome (PRO) measures may be useful as a prognostic marker for mortality and assist with treatment selection for patients with cutaneous chronic graft-vs-host disease (GVHD).


After years of dependence on systemic corticosteroids, ruxolitinib treatment was effective for an adolescent patient with graft-versus-host disease (GVHD) who was initially thought to have eosinophilic gastroenteritis.
Advertisement
Advertisement
Trending on AJMC
1
Withdrawal of Aid Could Cause Millions of Lives Lost to HIV
2
EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy
3
Recent FDA Approvals Expand Dermatology Options for Patients With Skin of Color
4
Mortality Gap Between Puerto Rico and the US Mainland Among Medicare Advantage Enrollees
5